329 related articles for article (PubMed ID: 30482212)
21. Adaptive image-guided radiotherapy (IGRT) eliminates the risk of biochemical failure caused by the bias of rectal distension in prostate cancer treatment planning: clinical evidence.
Park SS; Yan D; McGrath S; Dilworth JT; Liang J; Ye H; Krauss DJ; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):947-52. PubMed ID: 22208964
[TBL] [Abstract][Full Text] [Related]
22. Prostate Dose-painting Radiotherapy and Radiobiological Guided Optimisation Enhances the Therapeutic Ratio.
Uzan J; Nahum AE; Syndikus I
Clin Oncol (R Coll Radiol); 2016 Mar; 28(3):165-70. PubMed ID: 26482453
[TBL] [Abstract][Full Text] [Related]
23. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
24. Toxicity after post-prostatectomy image-guided intensity-modulated radiotherapy using Australian guidelines.
Chin S; Aherne NJ; Last A; Assareh H; Shakespeare TP
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):804-811. PubMed ID: 28623847
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial.
Tøndel H; Lund JÅ; Lydersen S; Wanderås AD; Aksnessæther B; Jensen CA; Kaasa S; Solberg A
Radiother Oncol; 2018 Feb; 126(2):229-235. PubMed ID: 29398152
[TBL] [Abstract][Full Text] [Related]
26. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
27. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray J; Griffin C; Gulliford S; Syndikus I; Staffurth J; Panades M; Scrase C; Parker C; Khoo V; Dean J; Mayles H; Mayles P; Thomas S; Naismith O; Baker A; Mossop H; Cruickshank C; Hall E; Dearnaley D;
Radiother Oncol; 2020 Jan; 142():62-71. PubMed ID: 31767473
[TBL] [Abstract][Full Text] [Related]
28. PTV margin definition in hypofractionated IGRT of localized prostate cancer using cone beam CT and orthogonal image pairs with fiducial markers.
Oehler C; Lang S; Dimmerling P; Bolesch C; Kloeck S; Tini A; Glanzmann C; Najafi Y; Studer G; Zwahlen DR
Radiat Oncol; 2014 Nov; 9():229. PubMed ID: 25384898
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
[TBL] [Abstract][Full Text] [Related]
30. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.
Guckenberger M; Ok S; Polat B; Sweeney RA; Flentje M
Strahlenther Onkol; 2010 Oct; 186(10):535-43. PubMed ID: 20890743
[TBL] [Abstract][Full Text] [Related]
31. The potential failure risk of the cone-beam computed tomography-based planning target volume margin definition for prostate image-guided radiotherapy based on a prospective single-institutional hybrid analysis.
Hirose K; Sato M; Hatayama Y; Kawaguchi H; Komai F; Sohma M; Obara H; Suzuki M; Tanaka M; Fujioka I; Ichise K; Takai Y; Aoki M
Radiat Oncol; 2018 Jun; 13(1):106. PubMed ID: 29880006
[TBL] [Abstract][Full Text] [Related]
32. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
[TBL] [Abstract][Full Text] [Related]
33. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.
Lips IM; Dehnad H; van Gils CH; Boeken Kruger AE; van der Heide UA; van Vulpen M
Radiat Oncol; 2008 May; 3():15. PubMed ID: 18495016
[TBL] [Abstract][Full Text] [Related]
34. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
35. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
[TBL] [Abstract][Full Text] [Related]
36. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
37. The impact of the three degrees-of-freedom fiducial marker-based setup compared to soft tissue-based setup in hypofractionated intensity-modulated radiotherapy for prostate cancer.
Tanabe S; Utsunomiya S; Abe E; Sato H; Ohta A; Sakai H; Yamada T; Kaidu M; Aoyama H
J Appl Clin Med Phys; 2019 Jun; 20(6):53-59. PubMed ID: 31054217
[TBL] [Abstract][Full Text] [Related]
38. Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy.
Happersett L; Wang P; Zhang P; Mechalakos J; Li G; Eley E; Zelefsky M; Mageras G; Damato AL; Hunt M
J Appl Clin Med Phys; 2019 Jun; 20(6):120-124. PubMed ID: 31116478
[TBL] [Abstract][Full Text] [Related]
39. Target localization and toxicity in dose-escalated prostate radiotherapy with image-guided approach using daily planar kilovoltage imaging.
Nath SK; Sandhu AP; Sethi RA; Jensen LG; Rosario MD; Kane CJ; Parsons JK; Millard FE; Jiang SB; Rice RK; Pawlicki T; Mundt AJ
Technol Cancer Res Treat; 2011 Feb; 10(1):31-7. PubMed ID: 21214286
[TBL] [Abstract][Full Text] [Related]
40. Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments.
Korpics MC; Rokni M; Degnan M; Aydogan B; Liauw SL; Redler G
J Appl Clin Med Phys; 2020 Mar; 21(3):184-191. PubMed ID: 31981305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
